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Obesity is a chronic, low degree systemic inflammatory status. Microarray examination shows a disturbance in the 
expression of cytokine, chemokine, complementary protein and half of the other acute phase components in obese patients. 
Adiponectin is the hormone that increases insulin sensitivity, while its level decreases under condition of fatty tissue 
enlargement that occurs in obesity. Excessive weight causes the adipocyte cells and adipose tissues produce various types 
of mediators. The inflammatory process is the main cause of metabolic diseases, and the main role of adipose tissue in the 
inflammatory process is determined by the production of pro-inflammatory mediators and anti-inflammatory mediators. 
Adiponectin has an important anti-inflammatory effect on obesity. Adiponectin has an important anti-inflammatory effect 
on obesity. Adiponectin works on macrophage and monocyte to inhibit the production of pro-inflammatory cytokine and 
increase the expression of interleukin (IL)-10 and IL-1 receptor antagonists. Adiponectin reduces induction of intercellular 
adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 endothelial adhesion by TNF-α or resistin. In 
obese patients, it is characterized by resistance to adiponectin alongside a decrease and the possibility of adiponectin loss 
in the receptor population in liver and muscles, leading to low adiponectin level.
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Introduction
Overweight and obese are disorder or disease characterized 
by excessive accumulation of fat tissue in the body.1 
Overweight is defined as having a body mass index (BMI) 
between 25 and 29.9, while obese is defined as having a 
BMI of 30 or higher. Overweight and obese people, who 
are characterized by fat deposits, have experienced a 
chronic low-grade systemic inflammatory process. The 
results of microarray examination in obese patients indicate 
a disturbance in the expression of cytokine, chemokine, 
complementary protein and half of the other acute phase 
components. It has also been suggested that the theory 
that activation of non-specific immune system components 
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can be considered a factor that allows the development 
of obesity and inflammation associated with it. These 
mediators provide important systemic effects may lead to 
insulin resistance, metabolic disorder and cardiovascular 
disease in obese patients.2
 Obesity pathomechanism is based on the theory of 
inflammation, which is characterized by lipid accumulation 
in adipose tissue and expansion of fat mass leading to the 
initiation of the inflammatory process. It starts with adipose 
cells producing pro-inflammatory cytokines and chemokine, 
including tumor necrosis factor (TNF)-α, interleukin (IL)-6, 
leptin, resistin, monocyte chemoattractant protein (MCP)-
1, and plasminogen activator inhibitor (PAI)-1. Vascular 
endothelial cells respond through increased expression of 
adhesion molecules, which together with chemokine will 
attract immune cells, including monocyte-macrophages 
towards adipose tissue. Together, adipose cells, immune 
cells and endothelial cells and the resultant mediators will 
create an inflammatory environment that triggers insulin 
resistance. Pro-inflammatory mediators and proatherogenic 
mediators then enter the circulation, causing insulin 
resistance and increasing the risk of atherosclerosis.3
 Adiponectin,  an adipocytokine, has an important 
anti-inflammatory effect on obesity. In obese patients, 
it is characterized by resistance to adiponectin along 
with a decrease and the possibility of loss of adiponectin 
receptor population in liver and muscles, leading to low 
level of adiponectin. Adiponectine resistance occurs due 
to downregulation of adiponectin receptors (AdipoRs). 
Low level of adiponectin as anti-inflammatory will tend 
to aggravate the inflammatory process in obese people. 
Another report states that adiponectin is a key element at 
the molecular level that mediates the occurrence of insulin 
resistance in obese population.4
 The study was conducted by Eizadi, et al., in obese 
adult men, with an analysis using the Independent T test.5 
The samples show lower adiponectin level in obese men 
compared to men with normal weight (5.44±1.23 in the obese 
group and 7.56±1.32 in the normal weight group, p=0.021). 
Based on research by Bacha, et al., in obese adults, there 
is a decrease in adiponectin level at around 50% compared 
to adults of normal weight.6 In the obese adult group with 
more visceral fat tissues, they tend to have lower adiponectin 
level compared to obese people with less visceral fat tissues 
(6.2±0.9 and 9.0±1.0 µg/mL, p=0.05). This review intends 
to provide an explanation of the relationship and mechanism 
of adiponectin in the inflammatory process in obesity.
Adiponectin Molecules
Adiponectin is one of the adipocytokines that was first 
discovered in 1995 by Scherer. Adiponectin is also known 
as adipocyte complement related protein 30 kilodalton 
(ACRP 30), AdipoQ, adipose most abundant gene transcript 
(apM)-I and gelatin binding protein 28 kilodalton (GBP 
28).7 Adiponectin has gene mapping on chromosome 3q27. 
Several analyzes of single nucleotide polymorphisms (SNPs) 
and missense mutations, it was found that adiponectin gene 
is associated with the metabolic syndrome.8
Adiponectin Structure
Adiponectin is a protein formed from 247 amino acids 
consisting of 4 parts, namely amino acid terminals, variable 
regions, collagenous domains (cAd) and globular carboxy/
globular terminal C-terminal domains of adiponectin (gAd). 
Adiponectin includes a collagen superfamily that dissolves 
and has a homologous structure with collagen VIII and X 
factor, Clq complement factor and TNF family.9
 X-ray crystallography from gAd reveals a homologous 
structure with TNF-α. This indicates a link between 
evolutionary development between TNF-α and adiponectin. 
Both of these components have the opposite function, 
namely TNF-α as proinflammatory and adiponectin as anti-
inflammatory.7
 The basic form of adiponectin is a trimer which is 
formed by three rnonomer bonds in the globular domain. 
The monomer structure is not found to be circulated but is 
retained in adipocytes. Four to six trimers form a higher 
structure called oligomers with plasma concentrations of 
5-30 µg/L.7
 Plasma level of adiponectin ranges from 3.0-30 
µg/L, whereas adiponectin levels in cerebrospinal liquor 
is reported in 1-4% of serum level. Although it is not yet 
clear whether adiponectin can pass through the blood-brain 
barrier, there is evidence that mammalian adiponectin can. 
The half-life of adiponectin is approximately 14 hours.10
 Yamauchi separates 2 adiponectin receptors, AdipoRl 
and AdipoR2. Adipo R1 is produced more in skeletal 
muscles and adipoR2 in the liver. AdipoRl mediates the 
activation of peroxisome proliferators activator receptor 
(PPAR)-α, adenosin monophosphate activated proteinkinase 
(AMPK), glucose and β oxidation uptake, thus increasing 
gluconeogenesis. AdipoR2 is involved in the activation 
of PPAR nuclear receptors to mediate β oxidation and 
reception of reactive oxygen species (ROS).7
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 Two forms of receptors have been cloned for 
adiponectin with distinct distribution and affinity for the 
molecular form of protein. AdipoR1 is a receptor with high 
affinity for gAd, in contrast with full-length adiponectin 
(fAd), whilst AdipoR2 has intermedia affinity for both forms 
of adiponectin. AdipoR1 is expressed in skeletal muscle, 
while AdipoR2 is mainly expressed throughout the liver. 
Such finding is in line with observations that suggest that 
fAd has a greater effect on metabolic signals in the liver. 
Adiponectin may have an anti-tumor effect by acting as a 
negative regulator of angiogenesis by inducing endothelial 
cell apoptosis mediated by caspase. This effect is seen not 
to be affected by AMP-kinase intermediate signals. Besides, 
adiponectin has anti-inflammatory, anti-fibrotic effects on 
liver tissue, anti-diabetic and anti-lipidemic. AdipoR2 was 
found first in the liver, where AdipoR1 was reported to be 
found previously in skeletal muscles. Adiponectin level in 
plasma is significantly lower in obesity.11
Adiponectin Secretion
Adiponectin is synthesized in white fat cell tissues 
(adipocytes) and is produced during fat cell differentiation. 
The results show that adipose tissues are not only a place 
for storing fat, but also are endocrine organs that play an 
important role in interaction with endocrine, metabolic 
and inflammatory signals to regulate the body's energy 
homeostasis.12 Adiponectin was first discovered while 
examining gene expression in human’s visceral and 
subcutaneous fat tissue, which was aimed to determine 
the mechanism of diseases associated with obesity. 
Unexpectedly, genes expressed in subcutaneous and visceral 
fat tissue, at 20% and 30%, are genes that produce various 
kinds of bioactive secretory proteins (bioactive secretory 
protein), which are then called adipocytokine. One of these 
adipocytokines is adiponectin.13,14
 
Factors affecting Adiponectin Level
Gender influences the metabolic and endocrine function of 
adipose tissues. Women have a greater percentage of body 
fat than men. Increased adiposity in women is associated 
with larger fat cell size, increased lipolysis stimulation, 
increased triglyceride (TG) synthesis in this depot. This 
finding implies that female hormones play a significant 
role in these depot differences between genders, resulting 
in differences in adipocyte metabolism. Estrogen is a 
clear candidate and may mediate several differences in 
adipocyte metabolism. Sexual dimorphism is also related to 
differences in the distribution of the adiponectin complex in 
circulation.15,16
  A cross-sectional study involving 705 men, 262 
women in Japan, ages 30-65 years, BMI of 22.5±2.9 kg/
m2. Serum adiponectin concentration was measured using 
enzyme-linked immunosorbent assay (ELISA) method. 
Serum adiponectin concentration obtained in women 
(13.5±7.9 μg/L) was significantly higher than men (7.2±4.6 
μg/L).17 Adiponectin level is higher in women. It is assumed 
that influence of sexual hormone regulates adiponectin 
production.18
 Factors that also affect plasma adiponectin level 
are including circadian rhythm, showing the regulation 
of diurnal and pulsatile adiponectin secretion in humans. 
Adiponectin level reaches their peak in the morning and 
declines at night.19 Other factors that affect the expression 
and secretion of adiponectin are dietary factors. Fish oil and 
linoleic acid are also able to increase plasma adiponectin 
level, which is in line with the fact that consumption of 
these substances will provide a protective effect on diabetes 
mellitus.20 In contrast, diets with high carbohydrates and 
fats can reduce plasma adiponectin level.21 In addition, level 
of adiponectin plasma is negatively correlated with BMI, 
insulin resistance, TG, and low density lipoprotein (LDL) 
and is positively correlated with high density lipoprotein 
(HDL).17 High level of plasma adiponectin concentration 
were also found in thin individuals and patients with type 
1 diabetes mellitus, and level is low in patients with type 2 
diabetes mellitus and obese individuals.22
Adiponectin as Anti Inflammation
The role of adiponectin and TNF-α inhibits the production 
of one another in adipose tissues. C-reactive protein (CRP) 
expression is negatively regulated by adiponectin in fat 
tissues. Adiponectin expression is suppressed by IL-6 in fat 
tissues. Adiponectin inhibits monocyte adhesion and TNF-
α-induced adhesion molecular expression, macrophage 
transformation into foam cells, TNF-α expression in 
macrophage and smooth muscle cell proliferation.12,23
 Adiponectin can improve the negative impact of 
TNF-α on endothelial function. Without the need to inhibit 
the bonds of TNF-α and fAd, it can inhibit the adhesion 
molecules induced by TNF-α, VCAM-I, E-selectin and 
ICAM-I. Adiponectin suppresses inflammatory changes 
by inhibiting inhibitory nuclear factor kappa B (NF-kB) 
phosphorylation and NF-kB activation without affecting 
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activation of c-Jun N-terminal kinase (JNK), p38 and Akt 
which is activated by TNF-α. Adiponectin inhibits leukocyte 
colony formation, thus decreasing phagocytic activity and 
TNF-α secretion.24
 A Study reported that adiponectin inhibits cell 
proliferation induced by oxidized-LDL (oxLDL), inhibits 
superoxide secretion-induced, and activation of p42/p44 
MAPK by oxLDL. The impact of circulating oxLDL on the 
vascular wall results in foam cell formation, inactivation of 
endothelial nitric oxide (eNo), induction of inflammatory 
responses and formation of ROS. All these components are 
known to play an active role in the atherogenesis process.24
The Inflammatory Process induced by 
Changes in Adipose Tissues in Obesity
Obesity conditions are associated with chronic inflammation 
characterized by response to abnormal cytokine production 
and activation of inflammatory signaling pathways. Adipose 
tissues in obese patients are characterized by progressive 
inflammation and infiltration by macrophages. Changes 
in the size of adipocyte and fat cells cause physical 
changes in the surrounding area and modification of the 
paracrine function of adipocytes. In obesity, adipocyte 
cells will release low level of TNF-α, which can stimulate 
preadipocyte cells to produce chemoattractant, namely 
MCP-1. Similarly, endothelial cells also secrete MCP-1 
in response to cytokines. Therefore, both preadipocytes 
and endothelial cells can be responsible for attracting 
macrophages to adipose tissues.25
Adiposopathy is the accumulation of ectopic pathogenic 
adipocytes due to positive energy, sedentary, genetic, and 
environmental balance. The manifestation is a combination 
of adipocytes which are hypertrophy and ectopic, especially 
in the visceral. Such combination causes immunological 
and metabolic disorders.26 Adipocytes have dramatically 
varying cell sizes. Cell diameter can be about ten times as 
large and its volume becomes a thousand times bigger. This 
size affects the level of inflammation, lipid mobilization, and 
the pattern of adipocyte secretion. The spread of adipocytes 
in the abdomen is called the Android obesity pattern and 
those around the hips and thighs are called gynoid obesity 
pattern. From several studies, it is known that the form of 
android often describes fat accumulation in visceral organs 
associated with metabolic disorders including dyslipidemia, 
hypertension, and glucose intolerance.27
 Adipose tissues in non-obese individuals consist 
of a number of inflammatory cells and secretes various 
active substances; however, adipose tissues in obese 
individuals show more accumulation of macrophages and 
T cells, resulting in excessive amount of inflammatory 
mediators, such as MCP-1 and IL-6, and low adiponectin 
secretion. Increasingly large adipocyte cells will trigger 
stress in the endoplasmic reticulum (ER). Such condition 
is important in triggering inflammatory kinases, such as 
JNK and I-kappa-B kinase (IKK), which ultimately inhibit 
insulin signals and activate inflammatory cascades and 
inflammatory mediator production. The available evidence 
demonstrates that increased chemokine production, such 
as MCP-1 in obesity adipose tissues can increase the 
accumulation of macrophages. In tissues, monocytes 
and macrophages can be sources that secrete TNF-a. 
Cytokines, such as TNF-a and other stimuli, can lead to 
further activation of inflammatory kinases. Several studies 
have shown that T cells also accumulate in adipose tissues 
in obese individuals. Interferon-gamma (IFNγ), a typical 
T-helper 1 cytokine which possibly regulates the expression 
of TNF-a, MCP-1, and other inflammatory mediators, 
shows a role for adaptive immunity in the pathophysiology 
of obesity. Adipokines, such as IL-6, into the circulation can 
also trigger important systemic effects, such as increased 
production of acute inflammatory mediator in the liver and 
coagulation factors, which are likely to correlate with the 
incidence of atherothrombosis.2
 Increased secretion of leptin (and/or decreased 
production of adiponectin) secreted by adipocyte cells can 
also cause accumulation of macrophages by stimulating 
transport of macrophages towards adipose tissues and 
will also increase adhesion of macrophages to vascular 
endothelial cells. Physical damage to the endothelium, 
caused both by size changes and oxidative damage due 
to the more lipolytic environment, plays a role in the 
recruitment and accumulation of macrophage, similar to 
those seen in atherosclerosis. Any initial stimulus attracts 
macrophages into adipose tissue, but once these macrophage 
cells have infiltrated adipose tissue and become active, the 
macrophages together with adipocyte cells and other cell 
types will form a vicious circle of accumulation of larger 
withdrawal of macrophages, inflammatory production 
cytokines, and cause impaired adipocyte cell function.25
 Adipogenesis is the process by which precursor 
cells (preadipocytes) diffuse into mature adipocytes. 
During diffusion, there are morphological changes, 
cell development, fat accumulation, changes in insulin 
sensitivity, and adipokine expression.28 This mass 
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enlargement of adipocyte is a compensation for the insulin 
defect. Each adipocyte mass has a specific expression of 
the gene and responds differently to food, hormones, and 
temperature. Metabolically, active adipocytes found in the 
intra-abdominal, intra-muscular, perivascular and epicardial 
serve to provide energy for vital organs, such as liver, 
heart, blood vessels, and muscular muscles. However, the 
adipocytes in the omentum serve as sensors to regulate 
the diets eaten and distribute them from liver to the body 
through the mediation of autonomic neurons.29
 Apart from its anatomical location, the main 
difference between visceral and subcutaneous adipocytes 
is found in anabolic response, efficiency, proliferation, and 
in vitro differentiation. In mammals, adipocytes consist of 
2 types, which are white adipose tissue (WAT) and brown 
adipose tissue (BAT). WAT and BAT are divided on the 
basis of metabolic characteristics. WAT mainly serves to 
store excess energy for subsequent needs, whilst BAT is 
an energy-wasting organ. In experimental mice, BAT plays 
an important role to prevent and reduce obesity through 
increased energy disposal and heat production. The role 
of BAT in humans is unclear, because the number has 
drastically reduced in newborns; whereas in adults, 1 BAT 
is compared to 100-200 WAT.30
 There are two forms of macrophages in adipocytes, i.e., 
type M1 macrophage which serves to remove TNF-α, IL-
6, and increase inflammation; whilst M2-type macrophage 
serves to release anti-inflammatory cytokine, such as IL-
10 and repair tissues. Both of these macrophages decrease 
alongside the decrease in body weight.31 In some situations, 
macrophages can increase up to 40% in adipocytes. The 
mechanism of macrophage mobilization is unclear, possibly 
involving chemotaxic molecular secretion, and one of them 
is the C-C motif chemokine ligand 2 (CCL2) known as MCP-
1. CCL2 is the main C-C ligand of the chemokine receptor 
2 (CCR2) motive.32 As a result of adipocyte enlargement, 
the blood flow decreases; and if it cannot be compensated 
for by angiogenesis, there will be a disruption of perfusion 
and triglyceride clusters, followed by hypoxia. Hypoxia will 
stimulate the expression of angiogenic transcription factors, 
decreasing the expression of adiponectin, and PPAR-∂. 
Then adipocyte releases low level of TNF-α and stimulates 
preadipocyte to produce MCP-1. MCP-1 secretion aims to 
respond to the secretion of cytokine, leptin, and/ or decreased 
adiponectin secretion. All of these conditions can cause 
accumulation and increase in adhesion of macrophages to 
endothelial cells and adiposity.25
 TNF-α is the most important inflammatory mediator 
secreted by macrophages. TNF-α enhances the induction 
of other proinflammatory molecules, such as IL-6, IL-
8, MCP-1, and IL-1.33 Obstructing the development and 
differentiation of preadipocytes can be done by interfering 
with the insulin signal through a signaling mechanism of 
tyrosine phosphorylation, inhibiting serine phosphorylation, 
and down-regulation of several insulin signaling 
pathways. All of these conditions might result in insulin 
resistance, increase lipolysis, and decrease glucose uptake 
by adipocytes. The addition of anti TNF-α can inhibit 
inflammation in preadipocyte; and in adipocytes, dietary 
regulation in experimental animals can reduce MCP-1 and 
macrophages.33,34
 The biggest abnormality in visceral free fatty acid 
metabolism is the inability to suppress lipolysis due to 
hyperinsulinemia.35 Free fatty acids in the tissues will 
stimulate the production of destructive metabolite and cause 
structural abnormalities, necrosis, systemic inflammation, 
and endoplasmic reticulum stress. The saturated fatty acid 
bond with the 4th-like receptor-like macrophage (TLR-4) 
will activate NF-kB and TNF-α.36 Besides stimulating β-cell 
apoptosis, albumin increases expression of uncoupling 
protein (UCP)-2 and can further inhibit the production of 
adenosine triphosphate (ATP) needed for insulin secretion.37
The Relationship between Adiponectin and 
Inflammatory Process in Obesity
Previous research. revealed two important findings: first, 
obesity and type 2 diabetes were associated with low 
plasma adiponectin concentration and showed that this 
hypoadiponectinemia was evident in various ethnic groups 
with clear differences with the tendency in the obese 
group, type diabetes 2, and atherosclerosis. Second, the 
result shows that plasma adiponectin concentration is more 
closely related to insulin sensitivity and insulinemia level in 
fasting individuals compared with adiposity and glycemic 
condition. It suggests that hypoadiponectinemia in people 
with obesity and type 2 diabetes is largely due to insulin 
resistance and/ or hyperinsulinemia.22
 The results of other studies in Japanese individuals 
have shown that plasma adiponectin concentrations are 
negatively correlated with BMI and therefore the level is 
lower in obese subjects than thin subjects.38-40 These results 
indicate that plasma adiponectin concentration is inversely 
related to the percentage of body fat and similar condition 
is also found in various ethnic groups. Adiponectin is one 
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of the protein secreted by adipose. Despite being produced 
exclusively in white adipose tissue, adiponectin leves is low 
in obesity. This condition is also consistent with findings in 
mice, murine homologue of adiponectin, adipoQ which also 
experience down-regulation in obesity.41
Conclusion
Adiponectin is the hormone that increases insulin sensitivity 
and decreases levels in condition of fatty tissue enlargement 
occured in obesity. Adiponectin has an important anti-
inflammatory effect on obesity. Adiponectin works on 
macrophage and monocyte to inhibit the production of 
pro-inflammatory cytokine and increase the expression of 
IL-10 and IL-1 receptor antagonists. Adiponectin reduces 
induction of ICAM-1 and VCAM-1 endothelial adhesion 
by TNF-α or resistin. In obese patients, it is characterized 
by resistance to adiponectin together with a decrease and 
possible loss of adiponectin receptor population in the liver 
and muscles, leading to low adiponectin level. Low level 
of adiponectin as anti-inflammatory will tend to aggravate 
the inflammatory process in obese people. In contrast to 
adiponectin, leptin is a hormone released by adipocyte cells. 
If the amount of adipose tissue increases, adipocyte cells 
will produce more leptin; therefore the leptin concentration 
in plasma is positively associated with the mass of fatty 
tissues.
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